The the Swiss drugmaker will face off in the obesity area with leaders Novo Nordisk A/S and Indianapolis-based Eli Lilly and ...

In a report released today, Eric Le Berrigaud from Stifel Nicolaus maintained a Hold rating on Roche Holding AG (RHHVF – Research ...

The Temperature-Activated Generation of Signal (TAGS) technology was developed by Roche for its high-throughput PCR-based instruments.

The pharma company said it believes there’s plenty of room for multiple industry players in the obesity drug market.

The TAGS technology – or Temperature-Activated Generation of Signal to give it its full name – allows up to 15 diagnostic ...

Roche said it plans to focus on five key therapeutic areas as part of its new pharma strategy through 2030. The company will prioritize work in the areas of neurology, oncology and hematology, ...

Roche is rolling out what it describes as a new type of infectious disease diagnostic in Europe, with a single test capable ...

The TAGS technology has PCR testing capabilities on high-throughput systems such as the cobas 5800, 6800, and 8800 models.

Roche is narrowing its pipeline to 11 disease areas and continuing to invest in a targeted way, said Teresa Graham, chief ...

Roche is planning to launch 13 medicines by the end of the decade and cut research costs for new drugs by a fifth, according to a strategy update on Monday.

(RTTNews) - Swiss drug major Roche Group (RHHBY), at its Pharma Day 2024, said it expects sales momentum to continue into 2025, with strong growth by both divisions of Pharma and Diagnostics. The ...

Roche introduces cobas Respiratory flex test to use its TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses: Basel Wednesday, September 25, 2024, ...